MedTrace Logo

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

NCT00942734 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2025-05-01

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if RAD001 in combination with Tarceva (erlotinib hydrochloride) can help to control head and neck squamous cell cancer (HNSCC). The safety of this drug combination will also be studied.

Conditions

Interventions

DRUG

Erlotinib

One tablet (150 mg) by mouth every day of each 28 day study cycle.

DRUG

RAD001

1 tablet (5 mg) by mouth every day of each 28 day study cycle.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • OSI Pharmaceuticals

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Vali Papadimitrakopoulou, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00942734 on ClinicalTrials.gov